

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**


1/61

# *Figure 1*

Fusion of Cochleate Membrane with Target Cells



Phase/Fluorescent Image




Fluorescent Image

2/61

## Figure 2

### Formulation of Hydrophobic Cargo Moiety Into Cochleates: Solvent Drip Method




3/61

### *Figure 3*


#### Formulation of Hydrosoluble Cargo Moieties Into Cochleates:

Trapping method with preformed liposome




4/61

**Figure 4**




5/61

*Figure 5*




6/61

*Figure 6*



7/61


**Figure 7**






8/61

**Figure 8**




9/61




10/61

**Figure 10**  
**Survival Data**




11/61

*Figure 11*  
Comparison of Bacterial Burden for *in vivo* Study of AmB formulations



12/61




13/61


*Figure 13*




Re-suspended AmB Cochleates with 1.28% V-E (AmB to V-E w/w)



Re-suspended AmB Cochleates with 1.28% V-E (AmB to V-E w/w) and After Adding EDTA



Re-suspended AmB Cochleates with 1.28% V-E (AmB to V-E w/w)




Re-suspended AmB Cochleates with 1.28% V-E (AmB to V-E w/w) and After Adding EDTA

14/61

# Figure 14


## SURVIVAL DATA



15/61

**Figure 15**

Comparison of Bacterial Burden for in vivo Study of AmB formulations






16/61

**Figure 16**


*In Vitro* Efficacy of AmB Cochleates



17/61

**Figure 17**


Survival Data



18/61

**Figure 18**


Efficacy of CAMB formulations VS AmB/deoxycholate



19/61


**Figure 19**

Kinetics of Tyrphostin in Cochleates vs. Free




20/61

Figure 20



21/61


**Figure 21**



22/61


## Figure 22

ZnTPP In solution in 100% DMSO and in Cochleates



23/61

**Figure 23**






24/61

Figure 24

Cochleates using regular trapping method




25/61


**Figure 25**

ZnTPP in cochleates

After one hour



After 24 hours




26/61


**Figure 26**

ZnTPP in solution in DMSO

After one hour



After 24 hours




27/61


## Figure 27

Cochleates containing Pyrene DOPE

After 1 hour



After 24 hours




28/61


## Figure 28

Cochleates containing Pyrene DOPE and ZnTPP

After 1 hour



After 24 hours



29/61

Figure 29




Figure 30






Figure 31




30/61

Figure 32



31/61

Fluorescence





*Figure 33A*

*In vitro* uptake of Rho-PE-lipid  
precipitates

Lipid Precipitates Without  
Aggregation Inhibitor


Phase Contrast and Fluorescence



*Figure 33B*

*In vitro* uptake of Rho-PE-lipid  
precipitates

Lipid Precipitates With  
Aggregation Inhibitor





32/61

Figure 34B






Figure 34A




33/61

*Figure 35*

A. Rhodamine Cochleates With Half and Half



B. Rhodamine Cochleates With Whole Milk



C. Rhodamine-Cochleates With Evaporated Fat Free Milk




D. Rhodamine Cochleates Without Aggregation Inhibitor



34/61

*Figure 36*

A: Rhodamine Cochleates Prior to  
Addition of Milk



B: Rhodamine Cochleates With Milk



35/61

Figure 37A




Acetaminophen Lipid Precipitates With Casein



Acetaminophen Lipid Precipitates Without Casein


Figure 37B



Aspirin Lipid Precipitates With Casein




Aspirin Lipid Precipitates Without Casein



37/61


Figure 39

Gastric Irritation in Rat Model




38/61

*Figure 40*



39/61

*Figure 41*  
*In Vitro Efficacy of Anti-Inflammatory Cochleates*





40/61

Figure 43






Figure 42



41/61


*Figure 44*



42/61

*Figure 45*  
**Vancomycin**


A. Liposomes




B. Precipitates with casein



D. Precipitates w/o Casein  
upon addition of EDTA




C. Precipitates without Casein



43/61

Figure 46


Vancomycin Precipitate Efficacy @ 3hrs



In Vitro Efficacy of Vancomycin Precipitates in Macrophages Infected with *Staphylococcal aureus* at 3 hours post infection.

Figure 47

Vancomycin Precipitates Efficacy @ 6hrs




In Vitro Efficacy of Vancomycin Precipitates in Macrophages Infected with *Staphylococcal aureus* at 6 hours post infection.

45/61


Figure 48

Tobramycin


A. Liposomes




C. Precipitates without Casein



B. Precipitates with casein




D. Precipitates w/o Casein  
upon addition of EDIA



46/61

Figure 49


Efficacy of Tobramycin Formulations Against  
*Pseudomonas aeruginosa* at 3 Hours Post-Infection



47/61

*Figure 50*


Efficacy of Tobramycin Formulations Against  
*Pseudomonas aeruginosa* at 6 Hours Post-Infection






48/61

*Figure 51*




49/61

Figure 52



50/61


Figure 53



51/61

Figure 54

Particle size distribution of caspofungin lipid precipitates before  
and after the addition of BSA



52/61

Figure 55






Figure 56




54/61

*Figure 57*


Structure of caspofungin lipid precipitates as a function of pH.




pH=1




pH=6




pH=8



pH=4



pH=7









pH=9

55/61

*Figure 58*

AmB Cochleates Containing 0.2% (w/w) Parabens



0.1% (w/w) Methylcellulose


0.3% (w/w) Methylcellulose

0.5% (w/w) Methylcellulose




56/61

Figure 59



57/61


Figure 60



58/61


*Figure 61*

In vitro Efficacy of J774A




59/61

Figure 62



60/61

Figure 63



61/61

Figure 64

